Stockscreener 앱 받기
0.9811
0.11%
0.0011
전일 마감가:
$0.98
열려 있는:
$0.99
하루 거래량:
123.02K
Relative Volume:
0.18
시가총액:
$40.31M
수익:
-
순이익/손실:
$-66.88M
주가수익비율:
-0.5451
EPS:
-1.8
순현금흐름:
$-62.91M
1주 성능:
-0.89%
1개월 성능:
-8.31%
6개월 성능:
+15.17%
1년 성능:
+18.20%
1일 변동 폭
$0.9601
$0.99
1주일 범위
$0.922
$1.0098
52주 변동 폭
$0.63
$1.76
아킬레스 테라퓨틱스 Stock (ACHL) Company Profile
ACHL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACHL
Achilles Therapeutics Plc Adr
|
0.9811 | 40.31M | 0 | -66.88M | -62.91M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
아킬레스 테라퓨틱스 Stock (ACHL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-04-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-26 | 개시 | JP Morgan | Underweight |
| 2021-04-26 | 개시 | Oppenheimer | Outperform |
| 2021-04-26 | 개시 | Piper Sandler | Overweight |
모두보기
아킬레스 테라퓨틱스 주식(ACHL)의 최신 뉴스
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market - GlobeNewswire Inc.
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News
What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Achilles Therapeutics Announces Strategic Update - Yahoo Finance
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why - Yahoo New Zealand News
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why - Yahoo Sport Australia
Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study - Yahoo Lifestyle UK
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference - GlobeNewswire
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Yahoo Finance
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation - Quantisnow
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why - Nasdaq
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance
Novo (NVO) Posts Positive Data From Diabetes Study on CagriSema - Nasdaq
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board - GlobeNewswire
Achilles Therapeutics PlcADR Shares Close the Day 10.1% HigherDaily Wrap - Nasdaq
Achilles Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
아킬레스 테라퓨틱스 (ACHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):